Harvard Bioscience (HBIO) Return on Invested Capital (2013 - 2026)

Harvard Bioscience (HBIO) has reported Return on Invested Capital for 14 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (up 1.0% YoY), while the FY2024 annual figure was 0.0%, down 1.0% from the prior year.
• Return on Invested Capital improved to 0.0% in Q1 2026 per HBIO's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.0% in Q1 2023 and bottomed at 0.01% in Q1 2025.
• Historically, Return on Invested Capital has averaged 0.0% across 5 years, with a median of 0.0% in 2024.
• Annual changes were most pronounced in 2022 — Return on Invested Capital decreased 1 bps — and 2023, when it rose 1 bps.
• Harvard Bioscience's Return on Invested Capital stood at 0.01% in 2022, then surged by 117 bps to 0.0% in 2023, then tumbled by 285 bps to 0.0% in 2024, then plunged by 97 bps to 0.0% in 2025, then jumped by 100 bps to 0.0% in 2026.
• Business Quant data shows HBIO's Return on Invested Capital at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.